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Background: In animals, anogenital distance (AGD) at birth reflects androgen levels during pregnancy and predicts
adult AGD. Little is known about AGD in relation to female reproductive characteristics in humans, a question this
study was designed to explore.
Methods: We used multiple linear and logistic regression analyses to model the relationships between adult female
reproductive system characteristics (e.g. ovarian morphology, menstrual cycle) and two measures of AGD
[anus-fourchette (AGDAF) and anus-clitoris (AGDAC)] in 100 college-age volunteers in Spain. Ovarian morphology
was classified as having < 6 or ≥ 6 follicles per ovary.
Results: Both AGD measures were positively associated with ovarian follicle number, with AGDAF being more
strongly associated. Women in the upper tertile of the AGDAF and AGDAC distributions were more likely to have
≥ 6 ovarian follicles [OR: 6.0 (95% CI 2.0, 17.6) and 3.0 (95% CI 1.1, 8.6), respectively] compared to women in the
lowest tertile.
Conclusions: Increased follicular recruitment has been related to excess androgen exposure in utero in
toxicological studies. Our results suggest that the androgenic environment during early fetal life may influence
reproductive system development, including AGD, in human females.
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Anogenital distance (AGD) is routinely used as a develop-
mental endpoint in animal toxicology studies by the U.S.
Environmental Protection Agency and is one of the most
sensitive markers of in utero exposures to environmental
endocrine-disrupting chemicals (EDC) [1,2]. A number of
animal studies have shown that exogenous androgen or es-
trogen exposure (including EDC) during the prenatal
period can alter the development of the female reproductive
tract [3-15]. For example, bisphenol A (BPA), which may
have both estrogenic and anti-androgenic properties, has* Correspondence: jaime.mendiola@um.es
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reproduction in any medium, provided the orbeen shown to disrupt and alter ovarian function [10-14];
and it has recently been demonstrated that BPA alters early
oogenesis and follicle formation in the fetal ovary of nonhu-
man primates [14]. Moyer and Hixon [15] have recently
shown that prenatal exposure to another well-known EDC,
di(2-ethylhexyl) phthalate, increased the numbers of mature
follicles in adult females in the highest exposure group and
the subsequent decrease in overall reproductive lifespan. In
rodents, AGD reflects the amount of androgen to which a
female fetus is exposed in early development. Indeed, pre-
natal exposure of females to exogenous androgens results
in longer and more masculine AGD [5-7] and increased
ovarian follicular recruitment in adulthood compared to
controls [3,4,7]. In male rodents, shortened (weight-
adjusted) AGD persists into adulthood [16] and predicts
compromised reproductive function in the mature maleal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Landmarks for two measurements of AGD: AGDAC,
from the anterior clitoral surface to the center of the anus
(point 1 to point 3); and AGDAF, from the posterior fourchette
to the center of the anus (point 2 to point 3). Adapted with
permission from Sathyanarayana et al. [27].
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life-long read-out of prenatal androgen action [17].
Swan and colleagues showed a strong inverse associ-
ation between prenatal environmental exposure to the
anti-androgenic phthalates and shorter male AGD in
human infants [19,20]. Recently, several studies on adult
men have provided strong evidence of the relationship
between AGD length and male reproductive function
[21,22]. Thus, AGD may provide a reliable link between
prenatal hormonal milieu and adult reproductive func-
tion in human males as well. Less is known about AGD
in human females, but there are several published
reports of virilization of the lower urogenital tract after
either prenatal exogenous or endogenous exposure to
androgenic hormones [23,24]. Although a number of
studies have measured female AGD measurements in
human infants [19,20,23,25-27], to our knowledge, no
study has measured AGD in adult women. The aim of
this study is to investigate the relationship between




The Murcia Young Women’s Study (MYWS) is a cross-
sectional study of healthy young university students
(18–23 years old) in the Murcia region of Spain. MYWS
was carried out between 9th February 2011 and 25th
November 2011. Written informed consent was obtained
from all subjects. The Research Ethics Committee of the
University of Murcia approved this study.
Flyers stating, “Young healthy female university students
wanted for research project” were posted at university
campuses to invite students to participate in this study. To
be included in MYWS, subjects had to be university stu-
dents, have been born in Spain after 31st December 1987,
and be able to contact their mother and ask her to
complete a questionnaire. One hundred and twenty-four
students contacted us, 15 subjects did not meet inclusion
criteria (3 had not been born in Spain and 12 were born
before 31st December, 1987), leaving 109 (88%) eligible
students of whom 100 (92%) agreed to participate in the
study. At a scheduled clinic visit subjects underwent a
gynecological examination, including transvaginal ultra-
sound, and completed an epidemiological questionnaire
on lifestyle. Participants were compensated for their par-
ticipation (€40 gift card).
Physical examination and gynecological history
Body weight and height were measured using a digital
scale (Tanita SC 330-S, London, UK). Body mass index
(BMI) was calculated as weight in kilograms divided by
squared height in meters. Ovarian and uterine morph-
ology were studied by transvaginal ultrasound using asingle ultrasound machine for all imaging studies
(Voluson E8W; General Electric Healthcare, USA).
Women were scanned in the early follicular phase
(cycle days 1–6) by two gynecologists (75% by M.R.
and 25% by C.M.) using the same classification.
Uterine morphology was assessed as normal or abnor-
mal. Ovaries were classified as having < 6 or ≥ 6 follicles
per ovary [28-30], a cutoff which several studies suggest
may have clinical relevance [28,29]. All follicles fell in
the 2–10 mm diameter range. Having 6 or more follicles
has been associated with hyperprolactinaemia, hypothal-
amic anovulation or weight-related amenorrhoea and
may result from incomplete pulsatile gonadotrophin
(GnRH) stimulation of ovarian follicular development
[28]. It may also indicate an ovarian dysfunction in fe-
male adolescents with cystic fibrosis [29] or the presence
of polycystic ovary [30].
In addition, a complete gynecological history was
obtained from each subject, including history of
gynecological diseases (salpingitis, endometriosis, other)
(yes/no), self-reported menstrual cycle length (days) and
previous irregular menstrual cycle (yes/no).
Anogenital measurements
For each subject, AGD was measured in two ways. First,
AGDAC was measured from the anterior clitoral surface
to the center of the anus (Figure 1, point 1 to point 3).
Second, AGDAF was measured from the posterior four-
chette to the center of the anus (Figure 1, point 2 to
point 3). Measurements were made using a digital cali-
per (Stainless Steel Digital Caliper, VWRW International,
LLC, West Chester, PA, USA) and while subjects were
in the lithotomy position, with the thighs at a 45° angle
Table 1 Characteristics of young women participating in
the Murcia Young Women’s Study (MYWS)(1)
Mean (SD) Median (5–95)
Age (years) 20.0 (1.2) 20.0 (18.0-22.0)
BMI (kg/m2) 21.8 (3.1) 21.3 (17.7-28.8)
Age at menarche 12.7 (1.3) 13.0 (11.0-15.0)
Day of cycle at clinic 3.9 (2.6) 3.5 (1.0-6.0)
Menstrual cycle lengtha 30.9 (7.6) 30 (25.0-44.0)
Anogenital distance (AGDAC) (mm) 80.4 (10.5) 79.2 (59.5-96.1)
Anogenital distance (AGDAF) (mm) 37.7 (6.3) 37.2 (27.9-48.6)
AGDAF / AGDAC 0.47 (0.09) 0.46 (0.36-0.60)
Percentage of women (%)
Caucasian 98.0
Cigarette smokingb 34.0
Alcohol intake (liquor)c 31.6
Have had:
Good or excellent general healthd 92.0
Diabetes or thyroid disease 2.0
Using hormonal contraceptione 39.8
1) One woman with no physical examination performed (n = 99).
a) in days (number of subjects = 36).
b) Mean number ± (SD) of cigarettes per week, 39.4 ± (29.9), if a smoker.
c) Mean number ± (SD) of drinks (330 cc) per week, 2.6 ± (2.5), if a drinker.
d) Question was ‘How would you describe your own health?
e) Oral contraceptives or vaginal ring.
SD = Standard deviation; (5–95) = 5th-95th percentile.
AGDAC: Anogenital Distance from the center of the anus to the anterior clitoral
surface.
AGDAF: Anogenital Distance from the center of the anus to the posterior
fourchette.
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examiners made each of these measurements three
times, taking in total 6 measures for AGDAF and
AGDAC, respectively. The mean of the six measurements
was used as the estimate. Neither the examiners nor the
support staff had knowledge of any of the women’s pos-
sible conditions/alterations because the AGD measures
were taken before the gynecological examination.
Statistical analyses
We assessed intra- and inter-examiner variability in the
AGD measurements by calculating the coefficient of vari-
ation (% CV). We used multiple linear regression analyses
to identify predictors of each of the two AGD measure-
ments. Covariates initially examined as predictors of AGD
measurements were: age, height, weight, body mass index
(BMI; kg/m2), age at menarche, self-reported sexually trans-
mitted diseases (STD), taking any medication (antibiotics
or antihistamines; yes/no) and hormonal contraception
(yes/no). When inclusion of a potential covariate resulted
in a change in the β - coefficient of < 10%, the variable was
not retained in final models. Adjusted odds ratios (ORs)
and 95% confidence intervals (CIs) were calculated using
logistic regression. All tests were two-tailed and the level
of statistical significance was set at 0.05. Statistical ana-
lyses were performed with the statistical package IBM
SPSS 20.0 (IBM Corporation, Armonk, New York, USA).
Results
Table 1 shows the general characteristics of young
women attending the MYWS. The MYWS study popula-
tion was quite homogeneous. Participants were nullipar-
ous, mostly in good or excellent health, with neither
self-reported STD, nor injuries in the genital region, nor
transfusions. None of the women had been diagnosed
with salpingitis or endometriosis. Only one woman pre-
sented abnormality of the uterus (bicornuate uterus).
Sixty-five percent of the young women reported having
ever had irregular menstrual cycles. In terms of ovarian
morphology, 43% of the women presented < 6 ovarian
follicles and 57% ≥ 6 ovarian follicles. Women with < 6
follicles had a mean [± standard deviation (SD)] AGDAF
of 35.3 (5.3) mm and AGDAC of 77.3 (9.7) mm. Women
with ≥ 6 follicles had a mean AGDAF of 39.4 (6.5) mm
and AGDAC of 82.6 (10.7) mm.
The distributions of both AGDAC and AGDAF were ap-
proximately normal (Figure 2a,b). As expected, AGDAC
and AGDAF were correlated [Pearson correlation (r) = 0.44,
p < 0.0001] (Figure 3). In the multivariate analyses, there
was a significant positive association between BMI and
both AGD measures (both p < 0.01). Hormonal contracep-
tion was associated with shorter AGD measurements (both
p < 0.05) (Table 2). None of the other covariates were sig-
nificantly associated with either AGD measurement.As seen in Table 3, both AGDAF and AGDAC were posi-
tively associated with the presence of ≥ 6 ovarian follicles.
We also examined the association between having < 6 or
≥ 6 ovarian follicles and both AGD measurements stratified
in tertiles (33 women in each group). Both AGD measures
were significantly associated with having ≥ 6 ovarian follicles
after controlling for the same covariates used in the linear
regression models. Women with AGD in the upper tertile
of the AGDAC distribution, compared to the lowest tertile
were more likely to have ≥ 6 ovarian follicles compared to
< 6 follicles (Odds ratio: 3.0, 95% CI 1.1, 8.6). Similarly,
women in the middle and upper tertiles of the AGDAF dis-
tribution, compared to the lowest tertile, were three and six
times more likely to have ≥ 6 ovarian follicles compared to
< 6 follicles [Odds ratio: 3.2 (95% CI 1.1, 8.8) and 6.0 (95%
CI 2.0, 17.6), respectively]. Neither AGD measurement was
statistically significantly associated with any of the other re-
productive outcomes.Within and between-examiner variability
Intra-examiner coefficients of variation for both AGD
measurements were below 3%, and inter-examiner coef-
ficients of variation for AGDAC and AGDAF were 4.9%
Figure 2 Frequency distributions of (a) AGDAF and (b) AGDAC in the MYWS.
Mendiola et al. Environmental Health 2012, 11:90 Page 4 of 8
http://www.ehjournal.net/content/11/1/90and 10%, respectively. Using a mixed model, the inter-
class correlations were 0.84 (95% CI 0.76, 0.89) and 0.61
(95% CI 0.41, 0.74) for AGDAC and AGDAF, respectively.
Discussion
This is the first study to measure AGD in adult women
and examine the relationships between AGD and female
reproductive system characteristics. Both AGD measures
were positively and strongly associated with the presence
of greater ovarian follicular number. Moreover, a woman
with AGDAC or AGDAF in the highest tertile of thedistribution was 3 and 6 times, respectively, as likely to
have ≥ 6 ovarian follicles as a woman with an AGDAC or
AGDAF in the lowest tertile. This underscores the pos-
sible clinical implications of the associations that we are
reporting here.
Although we typically find that in men AGD measure-
ments are not sensitive to physiologic and lifestyle fac-
tors [22], in the current study population the use of
hormonal contraception was associated with shorter
measures in both AGD measurements (p values <0.05).



















Figure 3 Correlations between AGDAF and AGDAC measures in the MYWS.
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size (height or BMI) as in men, but also for hormonal
status in studies seeking associations with AGD mea-
surements. In our study population, 74% (n = 29) of the
young women taking hormonal contraception reported
irregular menstrual cycles in the previous three months.
However, no association was found between AGD mea-
surements and irregular menstrual cycle. Therefore we
could speculate that hormonal intake might be related
to the AGD measurements. To our knowledge, this is
the first time this association has been reported in
humans.
Recently, Dusek and Bartos [31] examined the effect of
the stage of the oestrous cycle on the AGD in female
mice and showed that AGD varied during the oestrous
cycle, and suggesting that female genital morphology
systematically varied within the oestrous cycle. Unfortu-
nately, all the AGD measures in our study were taken
during the early follicular phase, so that we cannot as-
sess that hypothesis. Nonetheless, it opens a door to the







BMI (kg/m2) 0.82 0.41
Hormonal
contraceptiona
- 2.4 - 0.20
a no vs. yes.contraception) could result in small fluctuations in
the morphology of the female external genitalia. Longi-
tudinal study measuring AGD within women at multiple
points in the cycles is needed to address this possibility.
Alternatively, it has been suggested that women using
hormonal contraception are somewhat more fertile than
women who do not [32]. In many mammalian species
females with shorter AGD are more fertile [33,34].
Therefore, it is possible that the shorter AGD we
observed in women using hormonal contraceptives
reflects increased fertility, rather than a direct effect of
hormone use on AGD.
As multiple animal studies have shown, the female re-
productive tract is susceptible to virilization by exogenous
androgen exposure prior to, as well as during, the in utero
masculinization programming window (MPW) [5-7]. This
prenatal hyperandrogenism results in enlarged cystic ovar-
ies, anovulation or increases ovarian follicular recruitment
in female offspring [3,4,7,35]. Excessive prenatal andro-
gens (either endogenous or exogenous) can produce a











< 0.01 1.2 0.34 < 0.01
0.03 - 4.9 - 0.24 0.01
Table 3 Multivariate analysis for young women’s female reproductive system characteristics and AGDAF and AGDAC
(1)
Variable AGDAF AGDAC
β 95% CI P-value R2 β 95% CI P-value R2
Uterine morphologya - 2.0 (− 9.7, 5.7) 0.60 0.22 1.0 (− 12.6, 14.6) 0.88 0.18
Ovarian morphology
< 6 ovarian follicles Ref. Ref.
≥ 6 ovarian follicles 3.1 (0.96, 5.3) < 0.01 0.30 4.6 (0.76, 8.5) 0.02 0.23
Menstrual cycle lengthb 0.25 (− 0.24, 0.74) 0.31 0.20 0.46 (− 0.62, 1.5) 0.39 0.23
Irregular menstrual cyclec 0.69 (− 1.6, 2.9) 0.55 0.22 0.71 (− 3.3, 4.8) 0.73 0.18
1) Controlling for BMI and hormonal contraception.
a) normal/abnormal.
b) in days (number of subjects = 36).
c) Question was: “Have you ever had an irregular menstrual cycle?” (yes/no).
β = Regression coefficient; CI = Confidence interval.
Ref.: reference group.
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widely hypothesized that the etiology of PCOS in humans
may include excess prenatal androgen exposure [37].
Pregnant women with PCOS have elevated circulating
concentrations of androgens at mid-gestation, which may
increase fetal androgen exposure, and female offspring of
PCOS mothers are at increased risk of altered ovarian
development and function [38,39]. Long-term follow-up
studies are required to determine whether this excessive
exposure resulted in long-term changes in ovarian func-
tion and/or alterations in reproductive function. Here, we
do not examine PCOS per se, however we do demonstrate
that AGD, a purported biomarker of prenatal androgen
exposure, is associated with increased ovarian follicle
number.
With regard to reproducibility of follicle count estimated
by transvaginal ultrasound, it has been shown that deter-
mination of follicle count by transvaginal ultrasound results
in acceptable intra- and inter- observer variability [40].
While there is undoubtedly some inter-cycle variability of
follicle count, it is considered to be of little clinical signifi-
cance, for example, in predicting the response in in vitro
fertilization [41]. Several articles have previously defined
having ≥ 6 or > 12 ovarian follicles as multifollicular [28,29]
or polycystic ovaries [30], respectively. We were unable to
look at women with polycystic ovaries separately due to
small numbers; only 10 women met this criterion. We
chose instead to use the cutoff for multifollicular ovary
(≥ 6), a cutoff which several studies suggest may have
clinical relevance [28-30].
We found significant positive associations between
both AGDAF and AGDAC and the presence of greater
ovarian follicle number, which could indicate a common
fetal origin between longer AGD and greater follicular
recruitment. In fact, in animal models, an association
between prenatal exposures to androgen excess and an
increase in ovarian follicular recruitment [3,4,7] and
longer AGD measurement [7] has been reported.All previous published studies on human female
infants have measured both AGDAF and AGDAC
[19,20,23,25-27]. Callegari et al. [23] also calculated the
ratio (i.e.: AGDAF/AGDAC) both, in premature/full-term
newborn infants and newborn infant girls with congeni-
tal adrenal hyperplasia, reporting a relatively higher ratio
among subjects with that condition. This result supports
the hypothesis that androgen exposure in utero may
affect measures of the anogenital region in human
females. Callegari et al. [23] also took both AGD mea-
surements on a small number of pregnant women (n = 10),
reporting the first such data, to the best of our knowledge.
With all the possible limitations regarding study popula-
tion and methodologies, our young women presented
longer AGDAF and shorter AGDAC compared to those ten
pregnant women.
We had only a few cases of clinically diagnosed PCOS
in our study population; therefore we were unable to
explore the relationship between that condition and the
AGD measures. A larger and more diverse population or
another type of study design (case–control) would add
much more information on whether androgen action
during early fetal life exerts a fundamental influence on
the female reproductive tract in humans, as has been
demonstrated in rodents.
Our population was small and limited in age and eth-
nicity, and thus cannot provide normative values for
human female AGD measurements. AGD measures
were well tolerated by all subjects, quick to perform,
with acceptable intra- and inter-examiner reliability. We
plan to assess reproductive hormones in a future publi-
cation. A finding of higher FSH and/or low inhibin-B,
estradiol or free testosterone with shorter or longer
AGD would lend support to the association between
AGD and female reproductive system characteristics
reported here.
In human males, shorter AGD in adulthood has been
associated with poorer semen quality [21,22] and
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disruption of testicular development in utero, as sug-
gested by the testicular dysgenesis syndrome hypothesis
[42,43]. As hypothesized, this syndrome, although poten-
tially multifactorial, may be caused by exposure to EDC
during the MPW [18].
Recently, Buck Louis et al. [44] suggested a similar
paradigm for human females, the ovarian dysgenesis
syndrome, which the authors define as alterations in
ovarian structure or function that may manifest as fe-
cundity impairments, gynecologic disorders, gravid dis-
eases or later onset of adult diseases. Environmental
exposures, particularly EDC, may be related to in utero
origin of gynecologic outcomes, which in turn would be
associated with later onset of adult diseases.
Conclusions
Animal studies have shown that the female reproductive
tract is susceptible to virilization by exogenous androgen
exposure prior to, as well as during, the MPW that is
determined by androgen action [6]. Our data demon-
strate associations between the two measurements of
AGD we examined and an increase in ovarian follicle
number. Our results suggest, therefore, that the andro-
genic environment during early fetal life may exert a
fundamental influence on both AGD and female repro-
ductive system characteristics in humans.
If AGD (adjusted for body size) is determined pre-
natally in humans as in rodents, a longer female AGD in
adulthood should reflect a longer AGD at birth, which
in turn may reflect increased androgen exposure in
utero. Therefore, both greater follicular recruitment and
longer AGD in adulthood - assuming that AGD is a
stable finding in humans throughout their lives - may
reflect a common origin in utero, resulting in alterations
of the developing female reproductive tract.
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